MOMETAMAX SINGLE DIN 02566672
Health Canada record
| Active ingredient(s) | MOMETASONE FUROATE MONOHYDRATE 2.1 MG; POSACONAZOLE 2.6 MG; GENTAMICIN SULFATE 8.6 MG |
|---|---|
| Dosage form | Suspension |
| Route | Otic |
| Schedule | PRESCRIPTION |
| Class | Veterinary |
| ATC | |
| Original market date | 04-Jun-2026 |
| Current status date | 04-Jun-2026 |
| Source | Health Canada DPD |
Establishment licence of the holder
Intervet Canada Corp. — licence 100147, currently licensed, last inspection rating C (2023-07-17).
No Canadian shortage report is currently matched to this DIN.
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 37094 | 2026-03-13 | New Drug Submission (NDS) |
International API supply for MOMETASONE FUROATE MONOHYDRATE
7 valid EDQM Certificates of Suitability from 7 holders. 12 active FDA Drug Master Files.
Request a quote for MOMETAMAX SINGLE